Jump to
Abstract
Rationale: Bone marrow (BM)–derived mesenchymal stem cells (MSCs) hold great promise for cardiovascular cell therapy owing to their multipotency and culture expandability.
Objective: The aim of the study was to investigate whether MSCs can treat experimental acute myocardial infarction (MI) and diabetic neuropathy.
Methods and Results: We isolated mononuclear cells from mouse BM and cultured MSCs in a conventional manner. Flow cytometry analyses of these cultured cells at passage 4 showed expression of typical MSC markers such as CD44 and CD29, but not hematopoietic markers such as c-kit, flk1, and CD34. To determine the therapeutic effects of MSCs, we injected MSCs into the peri-infarct area after ligation of the left anterior descending coronary arteries of mice and, as separate experiments, injected the same batch of MSCs into hindlimb muscles of mice with diabetic neuropathy. During the follow-up at 4 to 8 weeks after cell transplantation, growing tumors were observed in 30% of hearts in the MI model, and in 46% of hindlimbs in the diabetic neuropathy model. Histological examination of the tumors revealed hypercelluarity, pleomorphic nucleoli, cytological atypia and necrosis, and positive staining for α-smooth muscle actin, indicative of malignant sarcoma with myogenic differentiation. Chromosomal analysis of these MSCs showed multiple chromosomal aberrations including fusion, fragmentation, and ring formation.
Conclusions: Genetically unmodified MSCs can undergo chromosomal abnormalities even at early passages and form malignant tumors when transplanted in vivo. These results suggest that careful monitoring of chromosomal status is warranted when in vitro expanded MSCs are used for cell therapy such as for MI.
Isolated from various sources—including bone marrow (BM), cartilage, adipose tissue, amniotic fluids, and umbilical cord blood1,–,3—mesenchymal stem cells (MSCs) have drawn much attention for cell therapy because they can be easily expanded in vitro and differentiate into tissues of mesenchymal origin, including muscle, fibroblast, bone, tendon, ligament, and adipose tissue.4 Indeed, MSCs have been used for regenerating damaged tissues of noncardiac disorders such as stroke, Crohn disease, osteogenesis imperfecta, and graft versus host disease.5,–,8 Furthermore, MSCs have been used to regenerate cardiovascular tissues by virtue of their capability to transdifferentiate into cardiomyocytes and vessel-like cells.9,–,16 One pilot study reported that intracoronary injection of autologous MSCs could improve global and regional left ventricular function and reduce the size of the perfusion defect in patients with acute myocardial infarction (MI).17 However, recent studies argued against the transdifferentiation potential of MSCs and proposed that the main mechanism of MSCs on cardiovascular disease may be paracrine action.15,18,–,22 Accordingly, in this study, we designed experiments to elucidate the mechanism of BM-derived MSCs (BM-MSCs) in myocardial regeneration or repair.
Furthermore, we have attempted to treat diabetic peripheral neuropathy with BM-MSCs. Although diabetic neuropathy is the most common complication of diabetes mellitus, no effective therapy has been developed.23 Diabetic neuropathy is pathophysiologically associated with destruction of the vasa nervorum and loss of myelinated neurons.24 Recently, we have reported that endothelial progenitor cells and BM-derived mononuclear cells exert favorable therapeutic effects on diabetic neuropathy through their angiogenic and neurotrophic effects.24 Therefore, we sought to utilize MSCs for treating diabetic peripheral neuropathy on the basis of the angiogenic effects of MSCs.
On the other hand, concerns have been raised about the safety of MSCs for clinical use, with studies reporting the potential risk of in vitro expanded MSCs to develop tumors on transplantation. Human MSCs derived from adipose tissues became immortalized and spontaneously transformed after long-term culture, possibly because of augmented chromosome instability associated with dysregulation of telomere activity and cell cycle–related genes.25 Mice injected with these MSCs developed tumors in multiple organs. Similarly, mouse BM-MSCs can become transformed after long-term culture and induce tumors in mice.26,–,28 Chromosome instability, upregulated c-Myc expression, and elevated telomerase activity were suggested as contributing factors for acquiring malignancy in mouse BM-MSCs. In addition, the finding that a subpopulation of BM cells recruited to the stomach undergoing chronic infection became malignant and contributed to gastric cancer over time also suggests a tendency of BM-MSCs to be cancerous under certain conditions.29 In contrast, Bernardo et al30 reported that human BM-derived MSCs do not exhibit spontaneous transformation after long-term in vitro expansion, making this issue controversial. However, it was not reported whether nonmanipulated short-term cultured MSCs can acquire severe chromosomal abnormality and induce tumors in vivo.
In this study, using short-term cultured unmodified mouse BM-MSCs, we aimed to treat experimental diabetic neuropathy and MI. During 4 to 8 weeks of follow-up, rapidly growing tumors were observed in both models. Histopathologic studies revealed that these tumors were primitive sarcoma, and the BM-MSCs had chromosomal abnormalities even at early passages. This is the first study showing malignant tumor formation in the heart following implantation of any adult stem cells.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mouse bone marrow mononuclear cells were isolated from the femur and tibia of 8-week-old male C57/BL mice by density gradient centrifugation. Adherent cells were cultured on 10-cm plastic dishes in complete media consisting of Dulbecco's modified Eagle's media, 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 μmol/L l-glutamine. Diabetes mellitus was induced in 8-week-old male C57/BL mice by injection of streptozotocin (150 mg/kg in 0.9% saline). One million (1×106) MSCs were transplanted into limbs of the mice via bilateral intramuscular injection. Acute MI was induced by ligation of the left anterior descending coronary artery of mice. One hundred thousand (1×105) cultured MSCs were injected into the peri-infarct areas and apex. The sciatic nerves and hearts were stained with either hematoxylin and eosin (H & E) or antibodies against desmin and α-smooth muscle actin. Flow cytometry was performed by staining with phycoerythrin-conjugated antibodies against CD44, CD29, c-kit (CD117), CD31, and CD34. Chromosome analysis was performed at the Cytogenetics Core of the Dana Farber Harvard Cancer Center. Fifty cells were scored by determining the number of acrocentric chromosomes, fused chromosomes, chromosome fragments, and ring chromosomes.
Results
We locally injected cultured MSCs into the hindlimb muscles for treating diabetic neuropathy. In a first series of the study (n=10), we used MSCs at passages P3 to P4. In this experiment, 7 mice were euthanized at 2 and 4 weeks for histological analysis as scheduled. Another 3 mice, due to be euthanized at 8 weeks, died at 5 weeks. We believe that high blood glucose might have been responsible for the death of these mice, because diabetic control mice that did not receive MSCs sometimes died as well. In a second series of experiments, we injected MSCs at P4 to P6 in the same animal model (n=10). According to the study design, 7 mice were euthanized at 2 and 4 weeks for histological examination. The remaining 3 mice were scheduled to be euthanized at 8 weeks; however, 1 mouse died at 5 weeks, and 2 mice developed rapidly growing tumors in both hindlimbs between 5 and 8 weeks. These mice were euthanized at 8 weeks, and the tumors were harvested. In both series of experiments, we could not observe tumors by gross examination by 4 weeks.
Grossly, the tumors protruded visibly and were huge enough to cripple the hindlimbs (Figure 1A). The tumor covered the entire hindlimb that received the MSCs. Gross examination of the removed tumors demonstrated soft-flesh consistency, slippery surface, and multiple sites of necrosis (Figure 1A and 1B). Microscopic examination following H & E staining revealed fascicular arrangement of pleomorphic spindle cells, which is typical for myoma or sarcoma, and some areas of geographic necrosis due to rapid growth (Figure 1C). The tumor cells showed hypercelluarity, nuclear hyperchromatism, pleomorphic nucleoli, cytological atypia (Figure 1D), and increased mitotic figure, indicative of malignant sarcoma (Figure 1E and 1F). To more precisely determine the nature of the tumors, we performed immunostaining with antidesmin and anti-α-smooth muscle actin antibodies. The tumors were not stained for desmin but stained for α-smooth muscle actin, indicating that the tumors originated from smooth muscle cells (Figure 1G).
Transplanted MSCs generated malignant tumors in a mouse model of diabetic neuropathy. A, Representative tumors (arrows) in the hindlimbs following BM-MSC transplantation into hindlimb muscles. B, Serial cross-sectional images of the tumors showed multiple sites of necrosis (arrowheads). C–F, H & E staining showed fascicular arrangement of pleomorphic spindle cells and area of geographic necrosis (C, an arrowhead). The tumor cells showed nuclear hyperchromatism, pleomorphism, atypical mitosis (D, double arrows), and increased mitotic figures (E, arrows) suggesting pleomorphic sarcoma. The tumor cells were elongated and had abundant pinkish cytoplasms (F). The nuclei were centrally located and blunt ended. Original magnification ×400. Scale bar, 100 μm. G, Immunohistochemistry with α-smooth muscle actin showed that tumors were focally positive for α-smooth muscle actin, which is compatible with the pleomorphic sarcoma with myogenic differentiation. H, Positive control of α-smooth muscle actin staining (scale bar, 100 μm).
To further confirm the causal relationship of tumor and MSCs, we injected the same line of MSCs at P6 to P8 into the diabetic neuropathy model (n=15). In this series, 14 mice developed tumors at earlier time points (3 to 4 weeks) than in the second series of experiments. Only 1 mouse was free from gross tumor until 4 weeks. Together, tumors developed in 16 of 35 diabetic mice (46%) in 3 independent series of cell transplantation experiments for diabetic neuropathy (Table 1). There was a trend that later-passage MSCs induced tumors earlier and more frequently than did earlier-passage MSCs.
The Incidence of Sarcoma Formation
In another experiment, we sought to treat experimental MI with these MSCs. We used nondiabetic mice as an MI model to circumvent the effects of diabetes on tumor formation. We injected the same line of MSCs (1×105) at P6 to P10 into the peri-infarct area immediately after creation of MI (n=10). To monitor the development of tumors, we performed echocardiography every week. Until 6 weeks, we were not able to find any distinct masses; however, 1 mouse died at 7 weeks. During necropsy, infiltrating tumor was observed, which was extended into the posterior part of the heart (Figure 2). Because this finding suggests that our echocardiographic resolution may not clearly detect the occurrence of tumors, we euthanized all the mice and performed necropsy. Gross and microscopic examinations of these mice revealed that 3 of 10 mice (30%) had tumors at 7 weeks (Table 1).
Transplanted MSCs generated malignant tumors in a mouse model of acute myocardial infarction. A, Gross necropsy examination after opening the chest wall showed that the tumor mass (arrow) is extended to pericardial sac and invaded into the lung and chest wall. B and C, The explanted tumor showed infiltrative growth into the myocardium, pericardium, and chest wall. D, Light microscopic examination after H & E staining revealed infiltrative growth of hypercellular tumor surrounding almost one third of the heart and protruding out of heart. The tumor showed fascicular arrangement of atypical spindle cells having pleomorphic, hyperchromatic nuclei, and eosinophilic cytoplasm. Black scale bar, 1000 μm. White scale bar, 100 μm. LV = left ventricle; RV = right ventricle. E and F, IHC with α-smooth muscle actin showed that the tumor was focally positive for α-smooth muscle actin staining. Green fluorescence, α-smooth muscle actin; blue fluorescence, DAPI for nuclei. G, Positive control of α-smooth muscle actin staining (scale bar 100 μm).
By gross examination, tumors showed an invasive nature: tumors invaded internally into myocardium and externally into the pericardium and further into the lung and the chest wall (Figure 2A through 2C). Microscopic examination of H & E–stained cardiac tissues clearly demonstrated infiltrative growth of hypercellular tumors occupying one third of the myocardial wall and invading externally into the pericardium and the chest wall. The tumors showed fascicular arrangement of atypical spindle cells having pleomorphic, hyperchromatic nuclei, and eosinophilic cytoplasm (Figure 2D). Immunohistochemistry showed that the tumors were positive for α-smooth muscle actin (Figure 2E and 2F). These tumors were identified as the same type of tumors that were observed in the diabetic neuropathy model. On the basis of these gross and microscopic features, we diagnosed the tumors as spindle cell sarcoma with myogenic differentiation, which is a primitive and malignant type of sarcoma.
We wondered whether these MSCs had any phenotypic distinction from normal MSCs. We therefore investigated the cell biological characteristics of these tumor-forming MSCs using flow cytometry and chromosome analyses. The MSCs at P4 showed typical morphology of spindle cells (Figure 3A). Flow cytometry analysis demonstrated that 99% of these cells expressed typical MSC markers such as CD44 and CD29, and did not exhibit hematopoietic lineage markers such as c-kit, flk1, or CD34 (Figure 3B). We used BM mononuclear cells for culturing MSCs at the start, and there are usually contaminating hematopoietic lineage cells up to passage 2. Thus, passage 3 cells are regarded as the first clone of MSCs in our culture method. Chromosome analysis of these tumor-forming MSCs showed multiple chromosomal abnormalities including fusion, fragmentation, and ring formation (Figure 3D, Table 2 ). Such chromosome abnormalities were found in both P4 and P8 MSCs. These findings suggest that tumor-forming MSCs have chromosomal abnormalities without demonstrating any abnormal morphology or unusual surface epitopes of MSCs.
Characterization of tumor-forming MSCs. A, MSCs showed typical spindle-shaped morphology. Scale bar, 100 μm. B, Flow cytometry analysis showed that 99% of these MSCs expressed CD44 and CD29, but not c-kit, CD31, and CD34. C, Chromosome analyses of normal MSCs showed normal karyotype, 40 XY. D, Chromosome analyses of tumor-forming MSCs demonstrated multiple chromosomal abnormalities, including fusion, fragmentation, and ring formation.
Chromosome Analysis of MSCs
Discussion
We demonstrate that culture-expanded BM-MSCs possess chromosomal aberrations even at passage 4 of culture, and transplantation of these cells induces malignant tumors in mouse diabetic neuropathy and MI models. P4 is equivalent to passage 2 as an MSC line and can be usually obtained within 4 weeks of culture. This is often the minimum number of passages required to obtain enough cells to be used in preclinical or clinical studies. Clinical trials are underway using human MSCs for treating ischemic heart diseases.31 Because the heart is an organ that only rarely develops malignant tumors,32 the present study suggests the aggressiveness of anomalous MSCs and prompts more careful attention to the potential side effects of cell therapy using MSCs in humans.
MSCs have been widely used for regenerating bone, cartilage, skeletal muscle, and even neural tissues in patients as well as in animal models, because of their multipotency.33,34 However, tumor formation has not been reported in animal or human studies to date with adult stem cells including MSCs that were passaged for short-term periods without genetic modification. Recently, spontaneous transformation of BM-derived rat MSCs—with abnormalities in cell morphology, cell proliferation rate, surface marker expression, and chromosome number—was found at passages as early as passage 3, whereas no tumors were observed in any organs in nude mice after intravenous injection of these transformed MSCs.35 There was a report of sarcoma formation by cultured mouse MSCs that had been genetically modified using transposons.26 On the other hand, there have been 2 reports that late-passaged mouse and human MSCs (P16 to P20) developed chromosomal abnormalities and underwent spontaneous cancerous transformation in vitro and in vivo.25,27 The mechanism by which MSCs are transformed into malignant cells is known to be related to chromosomal abnormalities, including structural and numeric aberrations, and increases with higher passage numbers.27 Miura et al intentionally induced spontaneous immortalization after numerous passages (P29 to P54) and demonstrated a contribution of these transformed cells to fibrosarcoma formation in vivo. Rubio et al showed that although MSCs can be managed safely during the standard ex vivo expansion period (6 to 8 weeks), human MSCs can undergo spontaneous transformation following long-term in vitro culture (4 to 5 months), and the transformed cells lead to formation of tumors in mice.25 We used “unmodified” MSCs at early passages to avoid potential chromosomal abnormalities that result from long-term culture. However, these MSCs developed chromosomal abnormalities and induced malignant tumors when injected in vivo, although the cells display conventional morphology and surface marker characteristics. The accelerated rate of tumor formation by P6 to P10 MSCs in comparison with P4 to P6 MSCs suggest that cumulative abnormalities through ex vivo culture expansion is likely to promote tumorigenesis in vivo. Studies including ours suggested that sarcoma could originate from implanted MSCs with altered chromosomal stability. It is also possible that tumors could be formed by fusion between the MSCs and resident smooth muscle cells, or that they originate from resident smooth muscle cells stimulated by the MSCs.27 The possibility of MSC-released cytokines transforming unidentified host cells into tumor cells is unlikely. As our experimental results indicate, tumors were formed regardless of the host organs (here, skeletal muscle or hearts) that were treated with the same MSC transplantation; albeit not excluded, this possibility appears to be minimal. Interestingly, opposing effects of MSCs have been reported on surrounding tumor growth. In general, because of their immunosuppressive actions, MSCs are known to favor tumor growth.36 However, studies have reported that MSCs may exert antitumorigenic effects in vitro and in a model of Kaposi sarcoma.37,38
For the past decade, clinical trials have been underway for treating cardiovascular diseases with various types of adult cells such as endothelial progenitor cells,39 MSCs,40 skeletal myoblasts,41 and BM mononuclear cells.42 Considering the choice of cells for regenerative therapy, safety should be considered as a priority in human use. From the standpoint of tumorigenic potential, more differentiated and uncultured cells may be beneficial; however, high inflammatory and tissue-calcifying activities of uncultured BM cells were reported to have side effects.43,44 Multipotency, on the other hand, can be associated with tumorigenic or unwanted cellular differentiation. Therefore, using selected uncultured cells such as CD34, CD133, or CD31 cells45 or short-term cultured cells may be a safer option for achieving neovascularization in ischemic cardiovascular diseases.
This is the first study to report that BM-derived MSCs could possess chromosomal abnormalities at very early passages of culture and that locally transplanted unmodified BM-derived MSCs could generate malignant tumors in cardiovascular animal models. Although this study did not use human MSCs, and the chromosomal aberrations are usually more common in mouse cells than in human cells, careful monitoring of chromosome status is warranted for using culture-expanded MSCs for cell therapy.
Sources of Funding
This work was supported in part by National Institutes of Health grants RO1HL084471, R21HL097353, RC1GM092035, P01GM85354, and HHSN268201000043C (Program of Excellence in Nanotechnology Award); and Stem Cell Research Center of the 21st Century Frontier Research Program grant SC4300, funded by the Ministry of Science and Technology, Republic of Korea.
Disclosures
None.
Acknowledgments
We would like to thank Andrea Wecker and Julie J. Kim for critical reading of the manuscript.
Footnotes
-
In February 2011, the average time from submission to first decision for all original research papers submitted to Circulation Research was 13.7 days.
-
Non-standard Abbreviations and Acronyms
- BM
- bone marrow
- MI
- myocardial infarction
- MSC
- mesenchymal stem cells
- Received December 28, 2010.
- Revision received March 25, 2011.
- Accepted April 1, 2011.
- © 2011 American Heart Association, Inc.
References
Novelty and Significance
What Is Known?
-
Bone marrow (BM)–derived mesenchymal stem cells (MSCs) hold a great promise for cell therapy because of their multipotency and their ability to expand in culture.
-
Experimental studies and pilot clinical trials have shown therapeutic benefits of BM-derived MSCs against ischemic heart disease.
What New Information Does This Article Contribute?
-
Unmodified mouse BM-derived MSCs exhibited chromosomal abnormalities even at early passages and induced malignant sarcoma when transplanted into hearts and hindlimbs.
We sought to test the potential of BM-derived MSCs for treating diabetic neuropathy and acute myocardial infarction on the basis of their multipotent differentiation potential and paracrine effects. We isolated mononuclear cells from mouse BM and cultured MSCs using conventional methods. During follow-up for 4 to 8 weeks after cell transplantation, growing tumors developed in 30% to 50% of the animals. Histopathologic examination revealed the identity of this tumor as malignant sarcomas, and chromosomal analysis showed multiple chromosomal aberrations of the injected MSCs. This study shows for the first time that genetically unaltered MSCs even at early passages can undergo chromosomal abnormalities and generate malignant sarcomas in vivo. These findings highlight the importance of the chromosomal status of MSCs and the requirement for close monitoring of chromosomal changes when cultured MSCs are used for cell therapy.
This Issue
Jump to
Article Tools
Share this Article
- Malignant Tumor Formation After Transplantation of Short-Term Cultured Bone Marrow Mesenchymal Stem Cells in Experimental Myocardial Infarction and Diabetic NeuropathyNovelty and Significance
